减肥
芬特明
医学
奥利斯特
利拉鲁肽
体重管理
安非他酮
肥胖
体重增加
肥胖管理
托吡酯
2型糖尿病
物理疗法
戒烟
内科学
糖尿病
体重
内分泌学
精神科
癫痫
病理
作者
George A. Bray,Gema Frühbeck,Donna H. Ryan,John Wilding
出处
期刊:The Lancet
[Elsevier BV]
日期:2016-02-10
卷期号:387 (10031): 1947-1956
被引量:882
标识
DOI:10.1016/s0140-6736(16)00271-3
摘要
A modern approach to obesity acknowledges the multifactorial determinants of weight gain and the health benefits to be derived from weight loss. Foundational to any weight loss effort is lifestyle change, diet, and increased physical activity. The approach should be a high quality diet to which patients will adhere accompanied by an exercise prescription describing frequency, intensity, type, and time with a minimum of 150 min moderate weekly activity. For patients who struggle with weight loss and who would receive health benefit from weight loss, management of medications that are contributing to weight gain and use of approved medications for chronic weight management along with lifestyle changes are appropriate. Medications approved in the USA or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phentermine/topiramate are also available. Surgical management (gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce remarkable health improvement and reduce mortality for patients with severe obesity.
科研通智能强力驱动
Strongly Powered by AbleSci AI